| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Stoller G et al. | An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl-prolyl cis/trans isomerase activity. | 1996 | FEBS Lett. | pmid:8612805 |
| Márquez JA and Serrano R | Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. | 1996 | FEBS Lett. | pmid:8612770 |
| Galat A | A note on circular-dichroic-constrained prediction of protein secondary structure. | 1996 | Eur. J. Biochem. | pmid:8612612 |
| Brousse N and Goulet O | Small bowel transplantation. | 1996 | BMJ | pmid:8611766 |
| Furth S et al. | Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. | 1996 | Pediatr. Nephrol. | pmid:8611359 |
| Johnson MW et al. | Hepatitis C viral infection in liver transplantation. | 1996 | Arch Surg | pmid:8611094 |
| Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
| Cacciarelli TV et al. | Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. | 1996 | Transplantation | pmid:8610416 |
| Hariharan S et al. | Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. | 1996 | Transplantation | pmid:8610411 |
| Yanchar NL et al. | Tacrolimus (FK506)--its effects on intestinal glucose transport. | 1996 | Transplantation | pmid:8610392 |
| Singh N et al. | Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. | 1996 | Transplantation | pmid:8610349 |
| Peters KP et al. | The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. | 1996 | J. Mol. Biol. | pmid:8609611 |
| Esquivel CO et al. | Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. | 1996 | Transplantation | pmid:8607198 |
| Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
| Suzuki S et al. | Pure red cell aplasia induced by FK506. | 1996 | Transplantation | pmid:8607191 |
| Greeno EW et al. | Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. | 1996 | Transfusion | pmid:8607158 |
| Fay JW et al. | FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. | 1996 | Blood | pmid:8605372 |
| Murao K et al. | Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH-releasing hormone in the rat. | 1996 | Endocrinology | pmid:8603582 |
| Vilquin JT et al. | Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. | 1996 | J. Cell Biol. | pmid:8601607 |
| Lake KD and Canafax DM | Important interactions of drugs with immunosuppressive agents used in transplant recipients. | 1995 | J. Antimicrob. Chemother. | pmid:8601538 |
| Rifai N et al. | The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. | 1996 | Clin. Biochem. | pmid:8601324 |
| Gruessner RW et al. | A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. | 1996 | Transplantation | pmid:8600635 |
| Inomata Y et al. | The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. | 1996 | Transplantation | pmid:8600632 |
| Beretta L et al. | Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. | 1996 | EMBO J. | pmid:8599949 |
| Ma J et al. | Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. | 1995 | Biophys. J. | pmid:8599646 |
| Dan Y et al. | IL-3 augments TCR-mediated responses of type 2 CD4 T cells. | 1996 | J. Immunol. | pmid:8598473 |
| Hammond TG and Kind CN | Pancreatic and nephrotoxicity of immunomodulator compounds. | 1995 | Toxicol. Lett. | pmid:8597171 |
| Taylor PJ et al. | Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. | 1996 | Clin. Chem. | pmid:8595724 |
| Sakane T et al. | [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. | 1995 | Ryumachi | pmid:8594659 |
| Dhar DK et al. | FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. | 1996 | J. Surg. Res. | pmid:8592405 |
| Cardenas ME et al. | Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. | 1995 | Curr. Opin. Nephrol. Hypertens. | pmid:8591053 |
| Lohse DL et al. | Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. | 1995 | Structure | pmid:8590008 |
| Jusko WJ et al. | Consensus document: therapeutic monitoring of tacrolimus (FK-506). | 1995 | Ther Drug Monit | pmid:8588229 |
| McMaster P et al. | Therapeutic drug monitoring of tacrolimus in clinical transplantation. | 1995 | Ther Drug Monit | pmid:8588228 |
| Jusko WJ | Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. | 1995 | Ther Drug Monit | pmid:8588227 |
| Fung JJ and Starzl TE | FK506 in solid organ transplantation. | 1995 | Ther Drug Monit | pmid:8588226 |
| Thomson AW et al. | Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. | 1995 | Ther Drug Monit | pmid:8588225 |
| Soldin SJ | Receptor (immunophilin-binding) assay for immunosuppressive drugs. | 1995 | Ther Drug Monit | pmid:8588223 |
| Goodall T et al. | FK506-induced endothelin release by cultured rat mesangial cells. | 1995 | J. Cardiovasc. Pharmacol. | pmid:8587453 |
| Takeda Y et al. | Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. | 1995 | J. Cardiovasc. Pharmacol. | pmid:8587392 |
| Büttemeyer R et al. | Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. | 1995 | Ann Plast Surg | pmid:8585683 |
| Gonschior AK et al. | Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. | 1995 | Ther Drug Monit | pmid:8585114 |
| Hemenway CS et al. | vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. | 1995 | Genetics | pmid:8582630 |
| Sekigawa I et al. | Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. | 1995 | J. Clin. Immunol. | pmid:8576317 |
| Wesselborg S et al. | Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). | 1996 | J. Biol. Chem. | pmid:8576111 |
| Sano T et al. | FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma. | 1995 | Eur. Respir. J. | pmid:8575571 |
| Vilquin JT et al. | FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. | 1995 | Hum. Gene Ther. | pmid:8573612 |
| Castillo Lugo JA | Clinical and experimental immunosuppression. | 1995 May-Jun | Bol Asoc Med P R | pmid:8573248 |
| Charters AR et al. | Developmental expression of FK506 binding proteins and calcineurin in rat brain. | 1995 | Biochem. Soc. Trans. | pmid:8566310 |
| Tanida I et al. | Yeast Cls2p/Csg2p localized on the endoplasmic reticulum membrane regulates a non-exchangeable intracellular Ca2+ pool cooperatively with calcineurin. | 1996 | FEBS Lett. | pmid:8566225 |
| Itoh S and Navia MA | Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). | 1995 | Protein Sci. | pmid:8563622 |
| Stillman IE et al. | FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. | 1995 | Lab. Invest. | pmid:8558840 |
| Ryffel B et al. | Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. | 1995 | Immunopharmacology | pmid:8557519 |
| Fukunaga T et al. | Osteogenesis in xenogeneic bone transplantation, using an immunosuppressant. Rabbit-rat experiments. | 1995 | Acta Orthop Scand | pmid:8553828 |
| Delaney CP et al. | Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. | 1996 | J. Clin. Invest. | pmid:8550837 |
| Koch K et al. | CP-123,369: a potent, orally active immunosuppressive agent. | 1995 | Inflamm. Res. | pmid:8548388 |
| Gharpure VS et al. | Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. | 1995 | Bone Marrow Transplant. | pmid:8547871 |
| Aoyama H et al. | Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. | 1995 | Br. J. Dermatol. | pmid:8547017 |
| Fryer JP et al. | Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. | 1996 | Arch Surg | pmid:8546583 |
| Shirakata Y et al. | Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. | 1995 | Transplantation | pmid:8545894 |
| Gjertson DW et al. | The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. | 1995 | Transplantation | pmid:8545861 |
| Andoh TF et al. | Functional and structural characteristics of experimental FK 506 nephrotoxicity. | 1995 | Clin. Exp. Pharmacol. Physiol. | pmid:8542679 |
| Jonas S et al. | Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. | 1995 | Clin Transplant | pmid:8541635 |
| Bersztel A et al. | Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. | 1995 | Transplant. Proc. | pmid:8540095 |
| Felldin M et al. | Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. | 1995 | Transplant. Proc. | pmid:8540032 |
| Tai J et al. | In vivo function of pig islet xenografts in immunosuppressed diabetic mice. | 1995 | Transplant. Proc. | pmid:8539968 |
| Wennberg L et al. | Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection. | 1995 | Transplant. Proc. | pmid:8539967 |
| Burke GW et al. | The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. | 1995 | Transplant. Proc. | pmid:8539874 |
| Burke GW et al. | Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. | 1995 | Transplant. Proc. | pmid:8539872 |
| Tesi RJ et al. | Conversion of pancreas transplants to FK 506 from CsA. | 1995 | Transplant. Proc. | pmid:8539828 |
| Swanson C et al. | FK 506-based immunosuppression in clinical pancreas transplantation. | 1995 | Transplant. Proc. | pmid:8539827 |
| Stratta RJ et al. | Preliminary experience with FK 506 in pancreas transplant recipients. | 1995 | Transplant. Proc. | pmid:8539823 |
| Henley SE et al. | Lipids following pancreas transplantation in recipients receiving FK 506. | 1995 | Transplant. Proc. | pmid:8539809 |
| Hariharan S et al. | Conversion from cyclosporine to tacrolimus after pancreas transplantation. | 1995 | Transplant. Proc. | pmid:8539799 |
| Groth CG | Immunosuppressive regimens of tomorrow. | 1995 | Transplant. Proc. | pmid:8539797 |
| Faerman CH and Karplus PA | Consensus preferred hydration sites in six FKBP12-drug complexes. | 1995 | Proteins | pmid:8539241 |
| Eckert B et al. | Calcium-mobilizing insulin secretagogues stimulate transcription that is directed by the cyclic adenosine 3',5'-monophosphate/calcium response element in a pancreatic islet beta-cell line. | 1996 | Endocrinology | pmid:8536617 |
| Ihara H et al. | Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. | 1995 | Int. J. Urol. | pmid:8536129 |
| Orengo CA et al. | Structural similarity between the pleckstrin homology domain and verotoxin: the problem of measuring and evaluating structural similarity. | 1995 | Protein Sci. | pmid:8535234 |
| Ockenfels HM et al. | Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. | 1995 | Dermatology (Basel) | pmid:8534940 |
| Zhu X et al. | Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells. | 1995 | Ann. Hematol. | pmid:8534762 |
| Kaplan A et al. | The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. | 1995 | J. Dermatol. Sci. | pmid:8534611 |
| Mugiya S et al. | Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. | 1995 | Thromb. Res. | pmid:8533130 |
| Büttemeyer R et al. | Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. | 1996 | Plast. Reconstr. Surg. | pmid:8532772 |
| Tamura K | FK506: mechanism of immunosuppression and adverse-effects. | 1995 | J Toxicol Sci | pmid:8531246 |
| Arreaza G et al. | Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. | 1995 | J. Clin. Endocrinol. Metab. | pmid:8530625 |
| Ku YM et al. | Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. | 1995 | Am J Health Syst Pharm | pmid:8528874 |
| Lionetti P et al. | Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. | 1995 | Adv. Exp. Med. Biol. | pmid:8525974 |
| Kissinger CR et al. | Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. | 1995 | Nature | pmid:8524402 |
| Cameron AM et al. | Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. | 1995 | Cell | pmid:8521476 |
| Krentz AJ et al. | Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. | 1993 | Diabetes | pmid:7694879 |
| Lhoëst G et al. | Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. | 1993 Sep-Oct | Drug Metab. Dispos. | pmid:7694828 |
| Zuany-Amorim C et al. | Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. | 1993 | Br. J. Pharmacol. | pmid:7694762 |
| White DJ | Immunosuppression for heart transplantation. | 1993 | Br. J. Biomed. Sci. | pmid:7694717 |
| Bierer BE et al. | Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. | 1993 | Curr. Opin. Immunol. | pmid:7694595 |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Jusko WJ and Kobayashi M | Therapeutic monitoring of tacrolimus (FK 506) | 1993 | Ther Drug Monit | pmid:7694395 |
| Travis J | Making molecular matches in the cell. | 1993 | Science | pmid:7694368 |
| Spencer DM et al. | Controlling signal transduction with synthetic ligands. | 1993 | Science | pmid:7694365 |
| Dawson TM et al. | Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. | 1993 | Proc. Natl. Acad. Sci. U.S.A. | pmid:7694293 |